



Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Phone: 03-3817-5120

Fax: 03-3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

No. 07-20

May 15, 2007

Eisai Co., Ltd.

Eisai Submits Application for Gastrokinetic Agent *Gasmotin*[®] in Thailand

On May 14 (local time in Thailand), Eisai (Thailand) Marketing Company Limited (Headquarters: Bangkok, President: Sithongsurapana Thaweesak), the Thai pharmaceutical sales subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) submitted an application to the Thai Food and Drug Administration for the gastrokinetic agent *Gasmotin*[®] (generic name: mosapride citrate) for the treatment of gastrointestinal symptoms associated with functional dyspepsia.

Gasmotin[®] is the gastrokinetic agent originally developed by Dainippon Sumitomo Pharma Co., Ltd. In April 2006, Eisai and Dainippon Sumitomo Pharma executed the license agreement which Dainippon Sumitomo Pharma granted to Eisai the rights for development, manufacturing and marketing of *Gasmotin*[®] in ten Asian countries including ASEAN members. This application in Thailand is the first application submitted since the license agreement was signed.

Gasmotin[®] is a selective serotonin 5-HT₄ receptor agonist which stimulates 5-HT₄ receptors in nerve plexuses in the gastrointestinal tract and has gastrokinetic and gastric evacuant effects by enhancing acetylcholine release.

Eisai is actively developing new business in Asian market with its global products including *Aricept*[®] (symptomatic treatment for Alzheimer's disease) and *Pariet*[®] (proton pump inhibitor), as well as utilizing various business alliances with its partners. In particular, Eisai has a solid basis for marketing in the gastroenterology area achieved by the experience with major gastritis/gastric ulcer treatments including *Pariet*[®] and *Selbex*[®]. The extension of the product lineup with *Gasmotin*[®] will bring greater synergy, allowing it to make further contributions to the greater numbers of patients in the market.

Eisai plans to make further efforts in order to achieve submission in other Asian countries and continues to make efforts for increasing the benefits to the patients in this region.

Contacts:

Corporate Communications Department

Eisai Co., Ltd.

81-3-3817-5120

###